Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biopharmaceutical innovator advancing oral therapies for cancer, liver diseases, and inflammatory conditions through its proprietary A3 adenosine receptor (A3AR) platform. This page serves as your definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and industry professionals will find curated press releases detailing progress across Can-Fite’s pipeline, including Phase II/III trials for Piclidenoson in psoriasis and Namodenoson’s dual applications in liver cancer and NASH. All content is verified through primary sources to ensure accuracy and timeliness.
Key updates cover regulatory milestones, partnership announcements, and peer-reviewed research findings. The collection emphasizes developments in targeted small molecule therapeutics while maintaining accessibility for both specialist and general audiences.
Bookmark this page to efficiently monitor Can-Fite’s advancements in addressing multi-billion dollar medical markets through its differentiated A3AR approach. Check regularly for critical updates that may influence market positioning and therapeutic innovation.
Can-Fite BioPharma (NYSE: CANF) has initiated a pivotal Phase 3 study for its oral drug Piclidenoson in treating moderate to severe plaque psoriasis, following protocol approval from both FDA and EMA. The study will begin enrolling patients in Europe, with US and Canada expected to follow.
The randomized, double-blind, placebo-controlled trial will evaluate 3mg twice daily oral Piclidenoson tablets versus placebo. The co-primary efficacy objectives include achieving a PASI 75 score and a Static Physician's Global Assessment of 0 or 1 at Week 16.
The FDA has requested two Phase 3 safety and efficacy studies and encouraged including adolescent patients due to the drug's strong safety profile. The company aims to submit a New Drug Application to the FDA and Marketing Authorization Plan to the EMA upon positive study conclusion. The psoriasis market is projected to reach $30 Billion by 2030, with a significant shift toward oral medications.
Can-Fite BioPharma (NYSE: CANF) announced that its partner Vetbiolix is launching an advanced clinical study for Piclidenoson in dogs with osteoarthritis, following a successful two-month clinical trial. The companion animal arthritis market, valued at $3.8 billion in 2023, is projected to reach $6.3 billion by 2030.
Piclidenoson is expected to capture up to 6% market share, with potential peak worldwide sales of $445 million by 2034. Can-Fite will receive a 15% royalty on worldwide sales, projecting aggregate revenues of $325 million over the next decade with an anticipated 2029 launch.
The drug offers advantages over current treatments, including oral NSAIDs with harmful side effects and injectable DMOADs. Piclidenoson presents a potentially safer and more effective oral treatment option, supported by favorable safety profiles in both human and animal studies.
Can-Fite BioPharma (NYSE American: CANF) has announced the completion of Phase II study design for Piclidenoson in treating Lowe Syndrome, a rare genetic disease. The open study, led by Dr. Franchesca Emma from Bambino Gesù Children's Hospital, will enroll 5 patients treated with 3 mg Piclidenoson twice daily for 12 months.
The study aims to evaluate Piclidenoson's efficacy in increasing 99mTc-DMSA renal uptake. This initiative follows successful pre-clinical work by Dr. Antonella De Matteis at the University of Naples Federico II. Can-Fite has partnered with Fondazione Telethon for the clinical development.
Lowe Syndrome, occurring mainly in males, affects approximately 1 in 500,000 people and causes vision problems, kidney issues, and brain abnormalities. The condition currently has no available drug treatment, and patients rarely live beyond 40 years. Pre-clinical studies showed Piclidenoson significantly decreased urinary protein loss, making it the only effective compound found among thousands tested.
Can-Fite BioPharma (NYSE American: CANF) announced FDA approval for compassionate use of its anti-cancer drug Namodenoson in a U.S. pancreatic cancer patient. Compassionate use allows physician-requested access to unapproved investigational drugs for serious diseases.
Namodenoson is currently undergoing multiple clinical trials, including LiverationTM, a pivotal Phase III study for advanced liver cancer approved by both FDA and EMA, and a Phase IIa pancreatic cancer study in Israel. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer, potentially providing seven years of market exclusivity post-approval along with regulatory advantages.
Can-Fite BioPharma (NYSE: CANF) announced the publication of an innovative study in the European Society of Medicine Journal highlighting the protective effects of Namodenoson in liver cancer treatment. The study, conducted in collaboration with hepatologists from Soroka University Medical Center, demonstrates the drug's anti-ischemic, anti-inflammatory, anti-fibrotic, and anti-toxicity properties across multiple body systems.
Unlike conventional chemotherapy, Namodenoson shows protective effects on the liver, central nervous system, and cardiovascular system by increasing adiponectin levels. The drug is currently in a pivotal Phase III study (LiverationTM) for advanced liver cancer, with both FDA and EMA approval. Notably, Namodenoson has received Orphan Drug status from both agencies and Fast Track status from the FDA.
Can-Fite BioPharma (NYSE American: CANF) reported significant clinical progress with its drug Namodenoson in treating decompensated liver cirrhosis under a compassionate use program. After 20 months of treatment, the patient showed notable improvements, including resolution of moderate ascites, no further gastrointestinal bleeding episodes, and decreased liver stiffness and globulin levels.
Dr. Ohad Etzion from Soroka Medical Center highlighted the drug's potential importance, given the treatment options currently available besides liver transplantation. The liver cirrhosis treatment market is projected to reach approximately $15 billion in the U.S. by 2030, addressing a global patient population of 10.6 million affected by decompensated cirrhosis as of 2017.
Can-Fite BioPharma (NYSE American: CANF) has announced an upcoming investor webinar scheduled for February 25, 2025, at 4:15 p.m. ET. The event will feature presentations from CEO Motti Farbstein and Executive Chairperson/CSO Dr. Pnina Fishman, focusing on the company's development pipeline and upcoming milestones.
The company has secured multiple out-licensing deals with potential regulatory and sales milestone payments exceeding $130 million, of which $20 million has already been received in upfront and milestone payments. Can-Fite's advanced-stage assets target markets valued at over $70 billion, positioning the company for potential commercialization of its therapies targeting oncological and inflammatory diseases.
Can-Fite BioPharma (NYSE American: CANF) has announced its participation in the BIO CEO & Investor Conference 2025, scheduled for February 10-11, 2025, in New York City. The company's Chief Executive & Chief Financial Officer, Motti Farbstein, will present on February 10 at 3:45 pm EST at the New York Marriott Marquis.
During the conference, management will conduct one-on-one meetings with investors and potential partners to discuss business strategy, clinical milestones, and development plans. The company's drug pipeline includes Namodenoson, currently in a pivotal Phase III trial for advanced liver cancer and a Phase IIb study for Metabolic Dysfunction-associated Steatohepatitis (MASH). Additionally, Piclidenoson is preparing to enter a pivotal Phase III trial for psoriasis.
Can-Fite BioPharma (NYSE American: CANF) announced that its lead drug candidate Namodenoson has been granted a US patent for use as an anti-obesity drug. The patent (No. 17/309,952), expiring in 2042, covers methods of treating obese patients with oral Namodenoson.
The drug demonstrated effectiveness by reducing fat levels through increased adiponectin hormone production and showed weight reduction in animal obesity models. In a Phase IIa MASH study, patients treated with Namodenoson experienced a 2.3% weight loss after 3 months with significant adiponectin level increases.
Namodenoson is currently in Phase IIb trials for MASH treatment, where most patients are obese. The global obesity treatment industry is projected to reach $60.5 billion by 2030, with an expected compound annual growth rate of 22.3% from 2025-2030.
Can-Fite BioPharma (NYSE American: CANF) announced that its research on Namodenoson's liver protective effects will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium. The company is currently conducting a pivotal Phase 3 multinational registrational trial for advanced liver cancer treatment. Notably, Namodenoson has shown remarkable results in one HCC patient who has remained cancer-free for over 8 years through a compassionate use program. The drug demonstrates dual benefits: anti-cancer activity and liver-protective effects, including anti-steatosis, anti-inflammatory, anti-fibrotic, and anti-ischemic properties. The protective mechanism works through adiponectin protein, which provides liver-, cardio-, and neuro-protective effects.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. (CANF)?
